This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • /
  • CAB-AXL-ADC Safety and Efficacy Study in Adults Wi...
Clinical trial

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Read time: 1 mins
Last updated:30th Apr 2021
Status: Recruiting
Identifier: NCT04681131
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Brief Summary:

The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC

Detailed Description:
This is a multi-center, open-label, Phase 2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC), alone and in combination with PD-1 inhibitor in patients with metastatic non-small cell lung cancer (NSCLC).

Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor
Estimated Study Start Date: May 2021
Estimated Primary Completion Date: December 2022
Estimated Study Completion Date: December 2022

- Experimental: CAB-AXL-ADC (BA3011)
- Experimental: CAB-AXL-ADC (BA3011)+PD-1 inhibitor

Category Value
Study type(s) Interventional
Estimated enrolment 240
Estimated Study start date 01 May 2021
Estimated Study Completion Date 01 December 2022

View full details